William L. Redmond

ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial

John Wrangle, Vamsidhar Velcheti, Manish R. Patel et al. · The Lancet Oncology · 2018 · 410 citations

Il-15 Superagonist, Medicine, Immunology +8

Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer

Julie N. Graff, Joshi J. Alumkal, Charles G. Drake et al. · Oncotarget · 2016 · 353 citations · Full text

Phenotypic and Functional Analysis of Cd8+ T Cells Undergoing Peripheral Deletion in Response to Cross-Presentation of Self-Antigen

Javier Hernández, Sandra Aung, William L. Redmond et al. · The Journal of Experimental Medicine · 2001 · 212 citations · Full text

OX40 Agonist Therapy Enhances CD8 Infiltration and Decreases Immune Suppression in the Tumor

Michael J. Gough, Carl E. Ruby, William L. Redmond et al. · Cancer Research · 2008 · 177 citations · Full text

Adjuvant Therapy With Agonistic Antibodies to CD134 (OX40) Increases Local Control After Surgical or Radiation Therapy of Cancer in Mice

Michael J. Gough, Marka R. Crittenden, Maryclare Sarff et al. · Journal of Immunotherapy · 2010 · 161 citations · Full text

Surgical Oncology, Tumor Recurrence, Immunology +21